342 related articles for article (PubMed ID: 16135784)
1. Proton activation does not alter antagonist interaction with the capsaicin-binding pocket of TRPV1.
Gavva NR; Tamir R; Klionsky L; Norman MH; Louis JC; Wild KD; Treanor JJ
Mol Pharmacol; 2005 Dec; 68(6):1524-33. PubMed ID: 16135784
[TBL] [Abstract][Full Text] [Related]
2. A polyclonal antibody to the prepore loop of transient receptor potential vanilloid type 1 blocks channel activation.
Klionsky L; Tamir R; Holzinger B; Bi X; Talvenheimo J; Kim H; Martin F; Louis JC; Treanor JJ; Gavva NR
J Pharmacol Exp Ther; 2006 Oct; 319(1):192-8. PubMed ID: 16844842
[TBL] [Abstract][Full Text] [Related]
3. N-(4-tertiarybutylphenyl)-4-(3-chloropyridin-2-yl)tetrahydropyrazine -1(2H)-carbox-amide (BCTC), a novel, orally effective vanilloid receptor 1 antagonist with analgesic properties: I. in vitro characterization and pharmacokinetic properties.
Valenzano KJ; Grant ER; Wu G; Hachicha M; Schmid L; Tafesse L; Sun Q; Rotshteyn Y; Francis J; Limberis J; Malik S; Whittemore ER; Hodges D
J Pharmacol Exp Ther; 2003 Jul; 306(1):377-86. PubMed ID: 12721338
[TBL] [Abstract][Full Text] [Related]
4. (R)-(5-tert-butyl-2,3-dihydro-1H-inden-1-yl)-3-(1H-indazol-4-yl)-urea (ABT-102) blocks polymodal activation of transient receptor potential vanilloid 1 receptors in vitro and heat-evoked firing of spinal dorsal horn neurons in vivo.
Surowy CS; Neelands TR; Bianchi BR; McGaraughty S; El Kouhen R; Han P; Chu KL; McDonald HA; Vos M; Niforatos W; Bayburt EK; Gomtsyan A; Lee CH; Honore P; Sullivan JP; Jarvis MF; Faltynek CR
J Pharmacol Exp Ther; 2008 Sep; 326(3):879-88. PubMed ID: 18515644
[TBL] [Abstract][Full Text] [Related]
5. Characterization of SB-705498, a potent and selective vanilloid receptor-1 (VR1/TRPV1) antagonist that inhibits the capsaicin-, acid-, and heat-mediated activation of the receptor.
Gunthorpe MJ; Hannan SL; Smart D; Jerman JC; Arpino S; Smith GD; Brough S; Wright J; Egerton J; Lappin SC; Holland VA; Winborn K; Thompson M; Rami HK; Randall A; Davis JB
J Pharmacol Exp Ther; 2007 Jun; 321(3):1183-92. PubMed ID: 17392405
[TBL] [Abstract][Full Text] [Related]
6. Conservation of functional and pharmacological properties in the distantly related temperature sensors TRVP1 and TRPM8.
Weil A; Moore SE; Waite NJ; Randall A; Gunthorpe MJ
Mol Pharmacol; 2005 Aug; 68(2):518-27. PubMed ID: 15911692
[TBL] [Abstract][Full Text] [Related]
7. TRPV1 receptor signaling mediates afferent nerve sensitization during colitis-induced motility disorders in rats.
De Schepper HU; De Man JG; Ruyssers NE; Deiteren A; Van Nassauw L; Timmermans JP; Martinet W; Herman AG; Pelckmans PA; De Winter BY
Am J Physiol Gastrointest Liver Physiol; 2008 Jan; 294(1):G245-53. PubMed ID: 17991707
[TBL] [Abstract][Full Text] [Related]
8. Antihyperalgesic effects of (R,E)-N-(2-hydroxy-2,3-dihydro-1H-inden-4-yl)-3-(2-(piperidin-1-yl)-4-(trifluoromethyl)phenyl)-acrylamide (AMG8562), a novel transient receptor potential vanilloid type 1 modulator that does not cause hyperthermia in rats.
Lehto SG; Tamir R; Deng H; Klionsky L; Kuang R; Le A; Lee D; Louis JC; Magal E; Manning BH; Rubino J; Surapaneni S; Tamayo N; Wang T; Wang J; Wang J; Wang W; Youngblood B; Zhang M; Zhu D; Norman MH; Gavva NR
J Pharmacol Exp Ther; 2008 Jul; 326(1):218-29. PubMed ID: 18420600
[TBL] [Abstract][Full Text] [Related]
9. Repeated administration of vanilloid receptor TRPV1 antagonists attenuates hyperthermia elicited by TRPV1 blockade.
Gavva NR; Bannon AW; Hovland DN; Lehto SG; Klionsky L; Surapaneni S; Immke DC; Henley C; Arik L; Bak A; Davis J; Ernst N; Hever G; Kuang R; Shi L; Tamir R; Wang J; Wang W; Zajic G; Zhu D; Norman MH; Louis JC; Magal E; Treanor JJ
J Pharmacol Exp Ther; 2007 Oct; 323(1):128-37. PubMed ID: 17652633
[TBL] [Abstract][Full Text] [Related]
10. Functional study on TRPV1-mediated signalling in the mouse small intestine: involvement of tachykinin receptors.
de Man JG; Boeckx S; Anguille S; de Winter BY; de Schepper HU; Herman AG; Pelckmans PA
Neurogastroenterol Motil; 2008 May; 20(5):546-56. PubMed ID: 18194153
[TBL] [Abstract][Full Text] [Related]
11. Differential involvement of TRPV1 receptors at the central and peripheral nerves in CFA-induced mechanical and thermal hyperalgesia.
Kanai Y; Hara T; Imai A; Sakakibara A
J Pharm Pharmacol; 2007 May; 59(5):733-8. PubMed ID: 17524240
[TBL] [Abstract][Full Text] [Related]
12. [3H]A-778317 [1-((R)-5-tert-butyl-indan-1-yl)-3-isoquinolin-5-yl-urea]: a novel, stereoselective, high-affinity antagonist is a useful radioligand for the human transient receptor potential vanilloid-1 (TRPV1) receptor.
Bianchi BR; El Kouhen R; Neelands TR; Lee CH; Gomtsyan A; Raja SN; Vaidyanathan SN; Surber B; McDonald HA; Surowy CS; Faltynek CR; Moreland RB; Jarvis MF; Puttfarcken PS
J Pharmacol Exp Ther; 2007 Oct; 323(1):285-93. PubMed ID: 17660385
[TBL] [Abstract][Full Text] [Related]
13. Pharmacologic antagonism of the oral aversive taste-directed response to capsaicin in a mouse brief access taste aversion assay.
Long DJ; Devantier HR; Brennan FX; Bryant RW; Salemme FR; Palmer RK
J Pharmacol Exp Ther; 2010 Feb; 332(2):525-30. PubMed ID: 19903834
[TBL] [Abstract][Full Text] [Related]
14. A-425619 [1-isoquinolin-5-yl-3-(4-trifluoromethyl-benzyl)-urea], a novel and selective transient receptor potential type V1 receptor antagonist, blocks channel activation by vanilloids, heat, and acid.
El Kouhen R; Surowy CS; Bianchi BR; Neelands TR; McDonald HA; Niforatos W; Gomtsyan A; Lee CH; Honore P; Sullivan JP; Jarvis MF; Faltynek CR
J Pharmacol Exp Ther; 2005 Jul; 314(1):400-9. PubMed ID: 15837819
[TBL] [Abstract][Full Text] [Related]
15. Involvement of an increased spinal TRPV1 sensitization through its up-regulation in mechanical allodynia of CCI rats.
Kanai Y; Nakazato E; Fujiuchi A; Hara T; Imai A
Neuropharmacology; 2005 Dec; 49(7):977-84. PubMed ID: 15998524
[TBL] [Abstract][Full Text] [Related]
16. Cloning and pharmacological characterization of mouse TRPV1.
Correll CC; Phelps PT; Anthes JC; Umland S; Greenfeder S
Neurosci Lett; 2004 Nov; 370(1):55-60. PubMed ID: 15489017
[TBL] [Abstract][Full Text] [Related]
17. Cloning and functional characterization of dog transient receptor potential vanilloid receptor-1 (TRPV1).
Phelps PT; Anthes JC; Correll CC
Eur J Pharmacol; 2005 Apr; 513(1-2):57-66. PubMed ID: 15878709
[TBL] [Abstract][Full Text] [Related]
18. Pharmacological characterization of (3S)-3-(hydroxymethyl)-4-(5-methylpyridin-2-yl)-N-[6-(2,2,2-trifluoroethoxy)pyridin-3-yl]-3,4-dihydro-2H-benzo[b][1,4]oxazine-8-carboxamide (JTS-653), a novel transient receptor potential vanilloid 1 antagonist.
Kitagawa Y; Miyai A; Usui K; Hamada Y; Deai K; Wada M; Koga Y; Sakata M; Hayashi M; Tominaga M; Matsushita M
J Pharmacol Exp Ther; 2012 Aug; 342(2):520-8. PubMed ID: 22588258
[TBL] [Abstract][Full Text] [Related]
19. N-(4-Tertiarybutylphenyl)-4-(3-cholorphyridin-2-yl)tetrahydropyrazine -1(2H)-carbox-amide (BCTC), a novel, orally effective vanilloid receptor 1 antagonist with analgesic properties: II. in vivo characterization in rat models of inflammatory and neuropathic pain.
Pomonis JD; Harrison JE; Mark L; Bristol DR; Valenzano KJ; Walker K
J Pharmacol Exp Ther; 2003 Jul; 306(1):387-93. PubMed ID: 12721336
[TBL] [Abstract][Full Text] [Related]
20. Amelioration of neuropathic pain by novel transient receptor potential vanilloid 1 antagonist AS1928370 in rats without hyperthermic effect.
Watabiki T; Kiso T; Kuramochi T; Yonezawa K; Tsuji N; Kohara A; Kakimoto S; Aoki T; Matsuoka N
J Pharmacol Exp Ther; 2011 Mar; 336(3):743-50. PubMed ID: 21098091
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
